Mirvetuximab soravtansine
About
Therapy type: Chemotherapy
Therapy strategy: Folate receptor-alpha inhibition
Mappings
NCI Thesaurus: Mirvetuximab Soravtansine (ncit:C102566)
RxNorm: mirvetuximab soravtansine (rxcui:2621548, omop:741947)
Therapeutic response
Precision oncology relationships for therapeutic response involving this therapy.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | FOLR1 positive | Ovarian Epithelial Tumor | Mirvetuximab soravtansine | |
| FDA (1) | FOLR1 positive | High-Grade Serous Fallopian Tube Cancer | Mirvetuximab soravtansine | |
| FDA (1) | FOLR1 positive | Peritoneal Serous Carcinoma | Mirvetuximab soravtansine |